Prime Medicine, Inc. · NASDAQ:PRME
ARCH Venture Fund X, L.P. reported a 10.40% stake in Prime Medicine, Inc. (Schedule 13D/A)
Event Aug 7, 2025 · Filed Aug 11, 2025
ARCH Venture Fund X, L.P. reported a 10.40% stake in Prime Medicine, Inc., 18,486,894 shares, with active intent on Aug 7, 2025. Filed Aug 11, 2025 (Schedule 13D/A).
- Stake
- 10.40%
- Shares
- 18,486,894
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 12 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| ARCH Venture Fund X, L.P. | 10.40% | 18,486,894 |
| ARCH Venture Fund X Overage, L.P. | 10.40% | 18,486,894 |
| ARCH Venture Fund XII, L.P. | 10.40% | 18,486,894 |
| ARCH Venture Partners X, L.P. | 10.40% | 18,486,894 |
| ARCH Venture Partners X Overage, L.P. | 10.40% | 18,486,894 |
| ARCH Venture Partners XII, L.P. | 10.40% | 18,486,894 |
| ARCH Venture Partners X, LLC | 10.40% | 18,486,894 |
| ARCH Venture Partners XII, LLC | 10.40% | 18,486,894 |
| Robert Nelsen | 10.40% | 18,587,036 |
| Keith Crandell | 10.40% | 18,486,894 |
| Kristina Burow | 10.40% | 18,486,894 |
| Steven Gillis | 10.40% | 18,486,894 |
Source
Related
- Prime Medicine, Inc.
- ARCH Venture Fund X, L.P.
- Prime Medicine, Inc. shareholders
- Schedule 13G/A · T. Rowe Price Investment Management, Inc. · Feb 17, 2026
- Schedule 13G · T. Rowe Price Investment Management, Inc. · Nov 14, 2025
- Schedule 13G/A · Alphabet Holdings LLC · Nov 12, 2025
- Schedule 13G/A · FMR LLC · Nov 5, 2025
- Schedule 13G/A · Newpath Partners, L.P. · Feb 14, 2025